Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isabelle Chabot

Showing results (1-10 of 22) with videos related to

Pageof 3
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinomaIsabelle Chabot, Angela Rocchi
Clinicoeconomics and Outcomes Research : CEOR|July 31, 2014
Oncology drug health technology assessment recommendations: Canadian versus UK experiencesIsabelle Chabot, Angela Rocchi
Clinicoeconomics and Outcomes Research : CEOR|June 18, 2015
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug ReviewAngela Rocchi, Isabelle Chabot, Judith Glennie
Current Medical Research and Opinion|October 12, 2020
Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancerIsabelle Chabot, Qi Zhao, Yun Su
European Journal of Cancer (Oxford, England : 1990)|March 29, 2008
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumourIsabelle Chabot, Jacques LeLorier, Martin E Blackstein
Arthritis and Rheumatism|February 8, 2006
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?Elham Rahme, Elke Hunsche, Youssef Toubouti, et al.
Vaccine|May 4, 2004
The societal value of universal childhood vaccinationIsabelle Chabot, Mireille M Goetghebeur, Jean-Pierre Grégoire
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 23, 2005
Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroidsMarc Dorais, Lucie Blais, Isabelle Chabot, et al.
The Annals of Pharmacotherapy|August 19, 2003
Pharmacist intervention program for control of hypertensionIsabelle Chabot, Jocelyne Moisan, Jean-Pierre Grégoire, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|November 24, 2004
Quality of life in hypertension: the SF-12 compared to the SF-36Isabelle Côté, Jean-Pierre Grégoire, Jocelyne Moisan, et al.
Pageof 3

Showing results (1-10 of 22) with videos related to

Sort By:
Pageof 3
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 22, 2010
How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinomaIsabelle Chabot, Angela Rocchi
Clinicoeconomics and Outcomes Research : CEOR|July 31, 2014
Oncology drug health technology assessment recommendations: Canadian versus UK experiencesIsabelle Chabot, Angela Rocchi
Clinicoeconomics and Outcomes Research : CEOR|June 18, 2015
Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug ReviewAngela Rocchi, Isabelle Chabot, Judith Glennie
Current Medical Research and Opinion|October 12, 2020
Systematic review of Real-World effectiveness of eribulin for locally advanced or metastatic breast cancerIsabelle Chabot, Qi Zhao, Yun Su
European Journal of Cancer (Oxford, England : 1990)|March 29, 2008
The challenge of conducting pharmacoeconomic evaluations in oncology using crossover trials: the example of sunitinib for gastrointestinal stromal tumourIsabelle Chabot, Jacques LeLorier, Martin E Blackstein
Arthritis and Rheumatism|February 8, 2006
Retrospective analysis of utilization patterns and cost implications of coxibs among seniors in Quebec, Canada: what is the potential impact of the withdrawal of rofecoxib?Elham Rahme, Elke Hunsche, Youssef Toubouti, et al.
Vaccine|May 4, 2004
The societal value of universal childhood vaccinationIsabelle Chabot, Mireille M Goetghebeur, Jean-Pierre Grégoire
The Journal of Asthma : Official Journal of the Association for the Care of Asthma|July 23, 2005
Treatment persistence with leukotriene receptor antagonists and inhaled corticosteroidsMarc Dorais, Lucie Blais, Isabelle Chabot, et al.
The Annals of Pharmacotherapy|August 19, 2003
Pharmacist intervention program for control of hypertensionIsabelle Chabot, Jocelyne Moisan, Jean-Pierre Grégoire, et al.
The Canadian Journal of Clinical Pharmacology = Journal Canadien De Pharmacologie Clinique|November 24, 2004
Quality of life in hypertension: the SF-12 compared to the SF-36Isabelle Côté, Jean-Pierre Grégoire, Jocelyne Moisan, et al.
Pageof 3